Antibody tests have been heralded as a crucial weapon in the battle against the Covid-19 pandemic. Although these tests are essential to helping epidemiologists better understand the disease and how it spreads, the precise antibodies developed against Covid-19 are also invaluable in discovering therapies to treat patients.
Berkeley Lights CEO Eric Hobbs notes it is going to take a while for vaccines to be approved, but “in the meantime, there is something that will help [tackle Covid-19]: antibody therapeutics.” Hobbs discusses how his company’s Beacon platform can support the development of these drugs against Covid-19, as well as future emerging pathogens.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Read the full story here.
